Patents by Inventor Tambra M. Dunams

Tambra M. Dunams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5366997
    Abstract: There are disclosed cardiovascularly active compounds possessing antihypertensive properties, and pharmaceutical compositions containing these agents and a method of treating cardiovascular disorders with the compounds. The active components of the pharmaceutical compositions are compounds of formula I ##STR1## wherein R.sub.1 and R.sub.2 are independently chosen from straight chain and branched chain alkyl and olefinic groups, which may be unsubstituted or substituted; or R.sub.1 and R.sub.2 together with the nitrogen atom they are bonded to form a heterocyclic group; and R.sub.3 is a pharmaceutically acceptable organic group selected from alkyl and olefinic groups which may be unsubstituted or substituted, acyl, a sulfonyl, sulfinyl, sulfenyl, carbonate, or carbamate derivative; or R.sub.3 is a group of the formula--(CH.sub.2).sub.n ONN(O)NR.sub.1 R.sub.2, wherein n is 2-8, and R.sub.1 and R.sub.2 are as described above. Novel compounds are disclosed wherein at least one of R.sub.1, R.sub.2 and R.sub.
    Type: Grant
    Filed: September 23, 1992
    Date of Patent: November 22, 1994
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Larry K. Keefer, Tambra M. Dunams, Joseph E. Saavedra
  • Patent number: 5212204
    Abstract: This invention concerns antihypertensive compositions and a method of lowering blood pressure in mammals. The active component of the compositions is a compound of the formula: ##STR1## wherein J is an organic or inorganic moiety, M.sup.+x is a pharmaceutically acceptable cation and the compound decomposes under physiological conditions to release nitric oxide (NO).
    Type: Grant
    Filed: October 18, 1989
    Date of Patent: May 18, 1993
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Larry K. Keefer, David A. Wink, Tambra M. Dunams, Joseph A. Hrabie
  • Patent number: 5208233
    Abstract: There are disclosed anti-hypertensive compositions and a method of lowering blood pressure in mammals. The active component in the anti-hypertensive compositions is a compound of the formula ##STR1## wherein R.sub.1 and R.sub.2 are independently selected from straight chain and branched chain C.sub.1 -C.sub.12 alkyl groups and benzyl, with the proviso that no branch occur on the alpha carbon atom of the alkyl group; or R.sub.1 and R.sub.2 together with the nitrogen atom they are bonded to form a heterocyclic ring; M.sup.+X is a pharmaceutically acceptable cation, wherein x is the valence of the cation.
    Type: Grant
    Filed: August 12, 1991
    Date of Patent: May 4, 1993
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Larry K. Keefer, David A. Wink, Tambra M. Dunams, Joseph A. Hrabie
  • Patent number: 5039705
    Abstract: This invention concerns anti-hypertensive compositions and a method of lowering blood pressure in mammals. The active component of the compositions is a compound of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are independently chosen from straight chain and branched chain C.sub.1 -C.sub.12 alkyl groups and benzyl, with the proviso that no branch occur on the alpha carbon atom of the alkyl groups; or R.sub.1 and R.sub.2 together with the nitrogen atom they are bonded to form a pyrrolidino, piperidino, piperazino or morpholino group, M.sup.+ is a pharmaceutically acceptable cation, wherein X is the valence of the cation.
    Type: Grant
    Filed: September 15, 1989
    Date of Patent: August 13, 1991
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Larry K. Keefer, David A. Wink, Tambra M. Dunams, Joseph A. Hrabie